Drug intelligence / Profile preview

PRO CAR-601

Development stage: Preclinical
Lead developer: PromiCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PRO CAR-601 is an investigational chimeric antigen receptor (CAR) T-cell therapy currently under development by PromiCell Therapeutics. As of early 2024, the asset is listed in the company's pipeline as an 'Additional Asset Under Negotiation.' While specific details regarding its biological target, mechanism of armoring (if any), and primary disease indications have not been publicly disclosed, its nomenclature suggests it is part of PromiCell's broader portfolio of CAR-T cell therapies aimed at treating various malignancies.

Beyond the preview

Go deeper on PRO CAR-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO CAR-601.

Explore the full profile